Welcome to our dedicated page for Orchard Therapeutics plc news (Ticker: ORTX), a resource for investors and traders seeking the latest updates and insights on Orchard Therapeutics plc stock.
Orchard Therapeutics plc (ORTX) is a pioneering biotechnology company dedicated to transforming the lives of children with life-threatening rare diseases through advanced gene therapies. The company focuses on the development, manufacturing, and commercialization of ground-breaking hematopoietic stem cell (HSC) gene therapies, which hold the potential to provide one-time treatments that address the underlying causes of severe genetic disorders.
Founded in 2015, Orchard Therapeutics collaborates with prestigious research centers globally to harness the life-saving potential of gene therapy. The company’s leadership team and partners bring over a decade of experience in advancing therapies for orphan diseases.
Orchard’s flagship product, Libmeldy® (atidarsagene autotemcel), is designed for the treatment of early-onset metachromatic leukodystrophy (MLD), a rare metabolic disorder. Libmeldy has received approval from the European Commission and the UK Medicines and Healthcare products Regulatory Agency and is under Priority Review by the U.S. FDA with a decision expected by March 18, 2024. The therapy aims to halt or slow disease progression by restoring enzymatic function.
The company is also advancing OTL-203 for mucopolysaccharidosis type I Hurler’s syndrome (MPS-IH) and OTL-201 for mucopolysaccharidosis type IIIA (MPS-IIIA), also known as Sanfilippo syndrome. These programs utilize the same HSC gene therapy platform as Libmeldy.
In a strategic move, Kyowa Kirin recently acquired Orchard Therapeutics, enhancing its portfolio with Orchard's clinically differentiated gene therapy platform. This acquisition is expected to drive the development of new treatments and support ongoing and future launches, including the continued growth of Libmeldy in Europe and potential new approvals in the U.S.
Orchard Therapeutics continues its mission to deliver curative gene therapies for severe diseases by translating promising early-stage research into approved treatments available to patients worldwide. The team remains committed to leveraging its extensive experience and cutting-edge technology to address unmet medical needs in rare and underserved conditions.
Orchard Therapeutics has appointed Braden Parker as Chief Commercial Officer (CCO) to lead the company's commercial strategy and operations. Parker, with over 20 years of experience in healthcare and biotech, is set to oversee the upcoming launch of Libmeldy™ in Europe, expected in 1H 2021. His background includes leadership roles at Celgene and PTC Therapeutics. Parker’s expertise in launching rare disease therapies aligns with the company's goal of evolving into a fully integrated commercial-stage organization, aiming to enhance the global growth strategy.
Orchard Therapeutics (ORTX) announces nine accepted abstracts for the 17th Annual WORLD Symposium, highlighting significant advancements in HSC gene therapy for neurodegenerative disorders. Key data includes clinical findings from eight patients treated with OTL-203 for MPS I and initial biomarker data from OTL-201 for MPS-IIIA. The upcoming symposium, from February 8-12, 2021, will feature discussions on transformative gene therapies, particularly OTL-200 for Metachromatic Leukodystrophy (MLD). A virtual investor webinar is scheduled on February 9, 2021, to review the data presented.
Orchard Therapeutics (Nasdaq: ORTX) is expanding its commercial presence in the Middle East and Turkey through exclusive collaborations with GenPharm Services and GEN. These partnerships aim to enhance access to Libmeldy, the first gene therapy approved for early-onset metachromatic leukodystrophy (MLD), which had EU approval in December 2020. The agreements facilitate treatment access for patients in seven additional markets: Saudi Arabia, Kuwait, UAE, Qatar, Bahrain, Oman, and Turkey. This initiative is crucial, as MLD is more prevalent in these regions.
Orchard Therapeutics announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to OTL-200, an ex vivo gene therapy for early-onset metachromatic leukodystrophy (MLD). This designation allows enhanced interaction with the FDA regarding the Biologics License Application (BLA) strategy. OTL-200 has previously been cleared by the FDA's Investigational New Drug (IND) application and received approval in the EU as Libmeldy. Data from clinical studies involving 39 patients will support the next regulatory steps.
Orchard Therapeutics (ORTX) has outlined its strategic priorities for 2021, aiming for the commercial launch of Libmeldy™ (OTL-200) for metachromatic leukodystrophy (MLD) in the EU in H1 2021. The company plans to file a Biologics License Application (BLA) for OTL-200 in the U.S. after discussions with the FDA by mid-2021. Additionally, an MAA for OTL-103 in Wiskott-Aldrich Syndrome (WAS) is on track for submission by year-end 2021 in the EU, with a U.S. BLA filing anticipated in 2022. Orchard reported $192 million in cash to fund operations through early 2022.
Orchard Therapeutics (Nasdaq: ORTX) will present at the 39th Annual J.P. Morgan Healthcare Conference virtually on January 13, 2021, at 9:10 AM ET. A live webcast will be accessible via the company's website, and a replay will be available post-presentation.
Orchard focuses on developing innovative gene therapies for rare diseases. Their ex vivo autologous gene therapy harnesses genetically modified blood stem cells to address the root causes of diseases. The company boasts a robust pipeline, having acquired GSK's rare disease gene therapy portfolio in 2018.
Orchard Therapeutics announced that the European Commission granted full marketing authorization for Libmeldy, the first gene therapy approved for eligible patients with early-onset metachromatic leukodystrophy (MLD). This one-time therapy uses a patient's own modified stem cells to potentially preserve motor and cognitive functions in children. The approval opens new treatment options for a devastating disease previously lacking approved therapies. Orchard is preparing for the commercial launch of Libmeldy across the EU.
Orchard Therapeutics (Nasdaq: ORTX) has revealed preliminary results from the OTL-201 gene therapy trial, aimed at treating mucopolysaccharidosis type IIIA (MPS-IIIA). Initial data from the first patient demonstrates significant therapeutic enzyme overexpression and a reduction in substrate levels after three months. The treatment showed promising safety profiles with no serious adverse events reported. With three patients treated, further follow-up and results are anticipated in 2021, highlighting the urgency of addressing this life-threatening condition.
BOSTON and LONDON, Nov. 24, 2020 — Orchard Therapeutics (Nasdaq: ORTX) announced CEO Bobby Gaspar will participate in a pre-recorded fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference. This chat will be available for on-demand viewing in the Investors & Media section of their website and will remain accessible for approximately 90 days. Orchard is committed to developing innovative gene therapies for rare diseases, with a robust pipeline following its acquisition of GSK’s gene therapy portfolio in 2018.
Orchard Therapeutics (Nasdaq: ORTX) received FDA clearance for its IND application for OTL-200, a gene therapy targeting metachromatic leukodystrophy (MLD), a severe neurodegenerative disease. OTL-200 has shown promise in clinical trials involving 39 patients, with follow-up data spanning up to eight years. The company aims to secure RMAT designation to facilitate discussions with the FDA for further development. The therapy addresses a significant unmet medical need as no approved treatments exist for MLD, which has a high mortality rate in young children.
FAQ
What is the market cap of Orchard Therapeutics plc (ORTX)?
What does Orchard Therapeutics specialize in?
What is Libmeldy?
Which regulatory approvals has Libmeldy received?
Who recently acquired Orchard Therapeutics?
What are Orchard Therapeutics' other clinical-stage programs?
When was Orchard Therapeutics founded?
What is the mission of Orchard Therapeutics?
How does Orchard Therapeutics' HSC gene therapy work?
Who is leading Orchard Therapeutics post-acquisition?
Where can I find more information about Orchard Therapeutics?
